Tardive Dyskinesia

New research on tardive dyskinesia has also been featured at the 2024 APA Annual Meeting.

This 2024 APA Annual Meeting poster estimated the prevalence of tardive dyskinesia in antipsychotic users in the US, and found rates ranging from 94.1-127.4 per 1000 antipsychotic users.

Deutetrabenazine extended-release tablets are now available.

A new, easy-to-use scale might be able to help clinicians determine the impact of tardive dyskinesia on patient functioning.

How do race, age, and gender correlate with the risk of tardive dyskinesia?

In this custom video series, Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, shares advice that can be helpful to community providers who manage children and adult patients prescribed antipsychotic therapy about screening for involuntary body movements and early signs of tardive dyskinesia.

In this custom video series, recommendations regarding patient selection and use of VMAT2 inhibitors in patients with tardive dyskinesia based on current clinical guidelines and real-world practice are shared.

In this custom video series, key opinion leaders compare VMAT2 inhibitors available for use to treat patients with tardive dyskinesia.

In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, caution against the use of anticholinergic medications for Parkinson’s disease and comment on the use of alternative therapies for appropriate patients.

In this custom video series, experts provide insight into strategies that may be helpful to healthcare professionals who manage patients on antipsychotic therapy to best monitor for signs of tardive dyskinesia, with special considerations regarding telepsychiatry.

In this custom video series, Leslie L. Citrome, MD, MPH, and Rose Mary Xavier, PhD, MS, RN, PMHNP-BC, reference the Abnormal Involuntary Movement Scale (AIMS) rating scale, used to assess the severity of involuntary movements and help diagnose tardive dyskinesia.

In this custom video series, key opinion leaders discuss what to know about the use of antipsychotic therapy and screening for signs of tardive dyskinesia, and starting treatment with a VMAT2 inhibitor.

What do we know about TD? What is on the horizon? Take the quiz to learn more.

Major risk factors for onset of tardive dyskinesia are considered.

What major challenges do patients with tardive dyskinesia face in their daily lives? Take the quiz and learn more.

The first study to gather unsolicited patient responses via social media finds 3 negative themes.

There are a few things that we all agree on, as reflected in a recent consensus statement.

Numbers don’t tell the whole story, but gaining a better sense of the frequency, risks, and impact on patients’ quality of life can help improve treatment efforts and enhance outcomes.

There are ways to prevent, manage, and treat TD, and this podcast will guide you through those steps from FDA-approved medications to off-label therapies.

Once thought untreatable, we now have two FDA-approved medications for TD and a handful of off-label options. More in this research update.

Tardive dyskinesia hits affected populations hard, especially older folks with poor support systems.

Recent studies and reviews report great progress in bringing TD under control.

A prediction model may help identify treatment characteristics associated with TD among patients with psychiatric disorders taking antipsychotic medications.

This video will help clinicians detect tardive dyskinesia and movement disorders in patients taking antipsychotic drugs.

In this quiz, learn which medical disorders patients with schizophrenia and comorbid TD are likely to contend with.

A program guide for the Abnormal Involuntary Movement Scale video.

Tardive syndromes include a broad spectrum of abnormal movements. Which movement disorders can resemble tardive dyskinesia? Find out in the quiz.

We’ve been waiting since 1953, the year chlorpromazine was introduced to the US as a revolutionary treatment for schizophrenia, for an active treatment for tardive dyskinesia that the FDA judged to be effective.

The results of a phase 3 trial demonstrated significant benefit over placebo.